Analyst: 'Mess Continues' With Amgen Neupogen Competitor By: Benzinga via Benzinga March 09, 2015 at 15:16 PM EDT Amgen, Inc. (NASDAQ: AMGN) will face competition for its Neupogen chemotherapy treatment from biotechnology, but exactly when a newly ... Read More >> Related Stocks: Amgen Novartis Ag ADR